ONC201 is a dopamine receptor inhibitor, DRD2, and is being evaluated as phase 2 clinical trial in neuroendocrine tumors including PHEO/PGLs [ClinicalTrials.gov Identifier: NCT03034200]. This evidence concerns the gene DRD2 and neuroendocrine neoplasm.